They are the leading player in the tech bio sector. They believe that while their business is facing significant headwinds they need to continue on their focus of using AI to decode biology. They took a major step to revolutionising drug discovery with their acquisition of Exscientia which is a company focused on using AI to revolutionise drug discovery. They first started by being a pioneer in phonemics which is now being used by every major pharmaceutical company in their discovery work stream. Unlike most biotech startups who optimise their first point solution thy have continued to invest into new tech to help with discovery and have even created the most powerful supercomputer in bio tech. They have strong breakthroughs in some of their medicines like one that can slow cancer growth by affecting the DNA damage reactions. Another one created fully by their AI has shown promising growth by already helping 5 people with the type of disease called platinum-resistant ovarian cancer. They continue to collaborate with other big Pharma companies from which till date they have generated 450 million in revenue and they believe they are under way to get up to 20 billion dollars in milestone payments because of all their collaborations. They are the biggest in their field and they are the closest compared to everyone else to get a predictive model which is almost always right. More than 90 percent of clinical trials fail so that’s why they are trying to use AI  and automation to be able to run million of digital tests with having the best results and accuracy. They create value in 3 ways by using their technology to try and find new medication in niche areas, discovering new medicines with large companies in areas like neuroscience and inflammation, and lastly they leverage their tools for the benefit of their partners. For this year they want to focus on monetising special assets to continue to fuel their spending. They are still not in the pivotal stage or the last stage of testing for any of their new drugs but a few of their drugs are in the last 2 stages. Because they acquired Exscientia they have the best in house AI stack for discovering drugs. Right now it takes over 10 years and around 2 billion dollars in R&D to create new drugs and they ar planning to take this opportunity and reduce time and cost by using AI. Some of the reasons that they differentiate from other people in the TechBio field is because of their full stack platform, wet lab and dry lab, and a significant scale already achieved. In 2021 they started their neuromap which is a effort to uncover insight into neurodegenerative disease. Overview. Recursion is a leading player in the TechBio sector and are focused on using AI to fin solutions to diseases. Thye are currently in the late stages for some of their products. They also partner up either big brands and help them with their research and in return get milestone rewards. They acquired Exscientia which is the second biggest player in the sector. Personal thoughts. I think that it is a very interesting business but is one with huge potential but also has a lot of risk. If even one of their products work it proves the potential of their sector but regulatory matters and how accurate AI is will be a big problem for them.